The Priority Review

Tag

Almirall

1 story

  1. Clinical trials

    Almirall registers Phase 3b trial of lebrikizumab in face and neck atopic dermatitis

    The study plans to enroll 230 participants and is expected to start in November 2026. It aims to evaluate the efficacy and safety of lebrikizumab for up to 32 weeks in adults and adolescents with moderate-to-severe face and neck atopic dermatitis who also have moderate-to-severe AD elsewhere and need systemic therapy.